List view / Grid view
26 October 2013 | By Just:: Health Communications
“These data show that RoActemra can continue to deliver meaningful improvements for people living with rheumatoid arthritis..."
25 October 2013 | By GlaxoSmithKline
"GSK has a vibrant and growing business in Brazil and we are delighted to announce our support for the new sustainable chemistry centre..."
25 October 2013 | By Abbott
"With the MitraClip system, heart teams now have a catheter-based, less-invasive treatment option..."
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
24 October 2013 | By Merck
The study evaluated the efficacy, immunogenicity and safety of V503 in females 16-26 years of age...
24 October 2013 | By AstraZeneca
The proposal to close the site has been made as the work undertaken at the laboratory is outside the organisation’s strategic focus...
24 October 2013 | By Amgen
McNamee will be responsible for leading a series of multi-year initiatives aimed at delivering growth and increasing productivity...
24 October 2013 | By Abbott
The annual survey is based on the views of working scientists...
23 October 2013 | By Stallergenes
Sublingual immunotherapy sales continued to grow in the 3rd quarter thanks notably to the fast adoption of Oralair® in France...
23 October 2013 | By Daiichi Sankyo Company
The researchers were selected from universities and public research centers in Japan...
23 October 2013 | By Sirius Analytical Instruments Ltd
Sirius Analytical Instruments Ltd announces the launch of a new product, the Sirius InForm...
23 October 2013 | By Chandler Chicco Agency
Positive opinion paves the way for a second aesthetic indication for VISTABEL® in 29 European countries...
22 October 2013 | By Novartis
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth..."
22 October 2013 | By AstraZeneca
SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone...
21 October 2013 | By College Hill
Dr Holland is an expert in biomarker-driven drug development...
